Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Breast cancer, early stage

122MO - Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib

Date

20 Sep 2021

Session

Mini oral session - Breast cancer, early stage

Topics

Tumour Site

Breast Cancer

Presenters

José García-Saenz

Citation

Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687

Authors

J.A. García-Saenz1, F. Marmé2, H.S. Rugo3, M. Untch4, H. Bonnefoi5, S. Kim6, H.D. Bear7, N. McCarthy8, K. Gelmon9, M. Martin10, C.M. Kelly11, T. Reimer12, M. Toi13, E.H. Law14, M. Gnant15, A. Makris16, S. Seiler17, N. Burchardi18, V. Nekljudova18, S. Loibl18

Author affiliations

  • 1 Service De Oncología Médica, Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC) and GEICAM, 28040 - Madrid/ES
  • 2 Gynecologic Oncology Department, UMM - Universitaetsklinikum Mannheim - Medizinische Fakultaet, 68167 - Mannheim/DE
  • 3 Department Of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 4 Department Of Gynecologic Oncology, Helios Klinikum Berlin-Buch, D-13125 - Berlin/DE
  • 5 Medical Oncology Department, Institute Bergonié and Universite´de Bordeaux INSERM U916, 33076 - Bordeaux/FR
  • 6 Oncology Dept., Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 7 Division Of Surgical Oncology, Massey Cancer Center, Virginia Commonwealth University, VCU Health, Richmond/US
  • 8 Medical Oncology, Breast Cancer Trials Australia and New Zealand and University of Queensland, Newcastle/AU
  • 9 Medical Oncology, BC Cancer Agency, Vancouver/CA
  • 10 Medical Oncology Service, Instituto de Investigacion Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense and GEICAM, Madrid/ES
  • 11 Medical Oncology, Breast Group Cancer Trials Ireland and Mater Misericordiae University Hospital, Dublin/IE
  • 12 Department Of Obstetrics And Gynecology, University of Rostock, 18059 - Rostock/DE
  • 13 Department Of Breast Surgery, Kyoto University Graduate School of Medicine, 606-8501 - Kyoto/JP
  • 14 Patient & Health Impact, Pfizer Inc., New York/US
  • 15 Comprehensive Cancer Center, Medical University of Vienna, Vienna/AT
  • 16 Clinical Oncology, Mount Vernon Cancer Centre, Northwood/GB
  • 17 Department Of Medicine And Research, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg/DE
  • 18 Department Of Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 122MO

Background

The PENELOPE-B trial did not demonstrate improved invasive disease-free survival with the addition of one year of palbociclib to endocrine therapy (ET) compared to placebo plus ET in high risk HR+/HER2- early breast cancer patients with residual invasive breast cancer following neoadjuvant therapy. This analysis compared patient-reported outcomes (PROs) between the two treatment groups.

Methods

Patients were randomized 1:1 to receive palbociclib 125 mg/day (n=631) or placebo (n=619) orally for 3 weeks followed by 1 week off plus ET per standard of care. PROs were assessed during screening, on day 1 of cycles 1, 3, 5, 7, 9, 11, then, every 6 months after end of treatment visit using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) and its breast cancer (BR23) and fatigue (FA13) modules. Higher scores of C30 and FA13 (range 0-100) indicate better functioning and global health status/quality of life (GHS/QoL) or worse symptom severity, respectively. Repeated-measures mixed-effects models were used to evaluate differences in PRO between treatment groups, changes of PRO over time, and treatment-by-time interactions.

Results

Overall, 924 of 1250 patients (73.9%) completed the baseline and at least one post baseline questionnaire of all PRO instruments. GHS/QoL by the EORTC QLQ-C30 was generally high in both treatment arms (mean [SD]: palbociclib 70.1 [19.3], placebo 71.4 [18.8]) and was slightly higher in the placebo arm (LeastSquare mean difference: 0.82, p<0.001), especially during the active treatment phase of the study. Higher fatigue was reported in the palbociclib compared to placebo arm (mean [SD]: 30.3 [23.8] vs. 28.3 [22.7]; p<0.001). In contrast, no statistically significant differences were observed among the FA13 physical, cognitive, and emotional fatigue subscales.

Conclusions

In general, patient-reported QoL and fatigue was maintained during the study in both treatment arms. Statistically significant differences were observed between treatments in favor of the placebo arm; however, none were clinically relevant.

Clinical trial identification

NCT01864746

Editorial acknowledgement

Legal entity responsible for the study

German Breast Group.

Funding

Pfizer Inc.

Disclosure

J.A. García-Saenz: Financial Interests, Personal, Funding: Lilly; Financial Interests, Personal, Funding: Pfizer; Financial Interests, Personal, Funding: Novartis; Financial Interests, Personal, Funding: Seagen; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Funding: Daiichi Sankyo; Financial Interests, Personal, Funding: MSD; Financial Interests, Other: Roche. F. Marmé: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Other: MSD; Financial Interests, Personal, Other: Clovis; Financial Interests, Personal, Other: GSK/Tesaro; Financial Interests, Personal, Other: Pfizer; Financial Interests, Personal, Other: Novartis; Financial Interests, Personal, Other: Lilly; Financial Interests, Personal, Other: Roche; Financial Interests, Personal, Other: Celgene; Financial Interests, Personal, Other: Seagen; Financial Interests, Personal, Other: Myriad; Financial Interests, Personal, Other: PharmaMar; Financial Interests, Personal, Other: Eisai; Financial Interests, Personal, Other: Janssen-Cilag. H.S. Rugo: Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Research Grant: Odonate; Financial Interests, Institutional, Research Grant: Daiichi; Financial Interests, Institutional, Research Grant: Seattle Genetics; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Institutional, Research Grant: Macrogenics; Financial Interests, Institutional, Research Grant: Sermonix; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: Polyphor; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Immunomedics; Financial Interests, Personal, Advisory Role: Puma; Financial Interests, Personal, Advisory Role: Mylan; Financial Interests, Personal, Advisory Role: Samsung. M. Untch: Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: AbbVie; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Amgen GmbH; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: AstraZeneca; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: BMS; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Celgene GmbH; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Daiji Sankyo; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Eisai GmbH; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Lilly Deutschland; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Lilly Int.; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: MSD Merck; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Mundipharma; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Myriad Genetics; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Pfizer GmbH; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Roche Pharma AG; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Sanofi Aventis Deutschland GmbH; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: TEVA Pharmaceuticals Ind Ltd; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Novartis; Financial Interests, Institutional, Funding, All fees to the institution/employer: Pierre Fabre; Non-Financial Interests, Institutional, Funding, All fees to the institution/employer: Clovis Oncology; Financial Interests, Institutional, Funding, All fees to the institution/employer: Seattle Genetics; Financial Interests, Institutional, Funding, All fees to the institution/employer: Seagen. S. Kim: Financial Interests, Institutional, Research Grant, institutional: Novartis; Financial Interests, Institutional, Research Grant, institutional: Sanofi-Aventis; Financial Interests, Institutional, Research Grant, institutional: DongKook Pharm Co; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Dae Hwa Pharmaceutical Co. Ltd; Financial Interests, Personal, Advisory Board: ISU Abxis; Financial Interests, Personal, Advisory Board: Daiichi-Sankyo; Financial Interests, Personal, Stocks/Shares: Genopeaks; Financial Interests, Personal, Stocks/Shares: NeogeneTC. H.D. Bear: Financial Interests, Personal, Research Grant: NSABP Foundation; Other, Personal, Stocks/Shares, Own stock in Pfizer: Pfizer. N. McCarthy: Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Specialised Therapeutics; Financial Interests, Personal, Advisory Role: Easai; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: AstraZeneca; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Roche; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Novartis. K. Gelmon: Financial Interests, Personal, Funding: Pfizer; Financial Interests, Personal, Funding: Eli Lilly; Financial Interests, Personal, Funding: AstraZeneca; Financial Interests, Personal, Funding: Novartis; Financial Interests, Personal, Funding: Seagen; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Eli Lilly; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Advisory Role: Mylan; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Nanostring; Financial Interests, Personal, Advisory Role: Genomic Health; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Seagen; Financial Interests, Personal, Expert Testimony: Genentech. M. Martin: Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Research Grant: Novartis; Financial Interests, Personal, Other: Daiichi Sankyo; Financial Interests, Personal, Funding: Lilly; Financial Interests, Personal, Research Grant: Puma; Financial Interests, Personal, Funding: AstraZeneca; Financial Interests, Personal, Funding: Pierre Fabre; Financial Interests, Personal, Funding: Pfizer. T. Reimer: Financial Interests, Personal, Funding: Pfizer. M. Toi: Financial Interests, Personal, Member of the Board of Directors: JBCRG association, Organisation for Oncology and Translational Research, Kyoto Breast Cancer Research Network; Financial Interests, Personal, Research Grant, Research grant, Lecture honoraria: Chugai; Financial Interests, Personal, Research Grant: Takeda; Financial Interests, Personal, Research Grant, Research grant, Lecture honoraria: Pfizer; Financial Interests, Personal, Research Grant, Research grant, Lecture honoraria, Advisory role for a drug development: Kyowa-Kirin; Financial Interests, Personal, Research Grant, Research grant, Lecture honoraria: Taiho; Financial Interests, Personal, Research Grant, Research grant: JBCRG association; Financial Interests, Personal, Research Grant, Research grant, Lecture honoraria: Eisai; Financial Interests, Personal, Research Grant, Research grant, Lecture honoraria, Advisory role for a drug development: Daiichi-Sankyo; Financial Interests, Personal, Research Grant, Research grant, Lecture honoraria: AstraZeneca; Financial Interests, Personal, Advisory Role, Lecture Honoraria, An advisory role: Eli Lilly; Financial Interests, Personal, Invited Speaker, Lecture Honoraria: MSD; Financial Interests, Personal, Invited Speaker, Lecture Honoraria: Exact Science; Financial Interests, Personal, Invited Speaker, Lecture Honoraria: Novartis; Financial Interests, Personal, Advisory Board, Honoraria for an advisory meeting: Konica Minolta; Financial Interests, Institutional, Research Grant, Research grant: Astellas; Financial Interests, Personal, Advisory Board, Honoraria for an advisory meeting: BMS; Financial Interests, Personal, Research Grant, Research grant, Lecture Honoraria: Shimadzu; Financial Interests, Personal, Research Grant, Research grant, Lecture Honoraria: Yakult; Financial Interests, Personal, Research Grant, Research Fund and Honoraria for lecture: Nippon Kayaku; Financial Interests, Institutional, Research Grant, Research grant: AFI technologies; Financial Interests, Personal, Advisory Role, An advisory role: Athenex Oncology; Financial Interests, Personal, Advisory Board, An advisory role: Bertis; Financial Interests, Personal, Advisory Board, An advisory role: Terumo; Financial Interests, Institutional, Research Grant, Research grant, an advisory role: Luxonus; Financial Interests, Institutional, Research Grant, Research grant: Shionogi; Financial Interests, Institutional, Research Grant, Research grant: GL Science; Financial Interests, Personal, Advisory Board, An advisory role: Kansai Medical Net. E.H. Law: Financial Interests, Personal, Full or part-time Employment: Pfizer Inc. M. Gnant: Financial Interests, Personal, Funding: Amgen; Financial Interests, Personal, Funding: Daiichi Sankyo; Financial Interests, Personal, Funding: AstraZeneca; Financial Interests, Personal, Funding: Eli Lilly; Financial Interests, Personal, Funding: LifeBrain; Financial Interests, Personal, Funding: Nanostring; Financial Interests, Personal, Funding: Novartis; Financial Interests, Personal, Funding: TLC Biopharmaceuticals; Other, Personal, Funding, an immediate family member is employed by Sandoz.: Sandoz. A. Makris: Financial Interests, Personal, Invited Speaker, Lectures for Pfizer: Pfizer; Financial Interests, Personal, Advisory Board, Advisory Boards with Pfizer: Pfizer. S. Loibl: Financial Interests, Institutional, Advisory Board, honorarium for Ad Boards & Lecture, paid to institute / Medical Writing: Pfizer; Financial Interests, Institutional, Advisory Board, honorarium for Ad Boards, paid to institute: AbbVie; Financial Interests, Institutional, Advisory Board, honorarium for Ad Boards, paid to institute: Amgen; Financial Interests, Institutional, Advisory Board, honorarium for Ad Boards & Lectures, paid to institute / Medical Writing: AstraZeneca; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board, paid to institute: Bayer; Non-Financial Interests, Institutional, Advisory Board, honorarium for Ad Board, paid to institute / Medical Writing: BMS; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board, paid to institute / Medical Writing: Celgene; Financial Interests, Personal, Invited Speaker, lecture: Chugai; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board & Lecture, paid to institute / Medical Writing: Daiichi-Sankyo; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board, paid to institute: Eirgenix; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board, paid to institute: GSK; Financial Interests, Institutional, Research Grant, paid to institute: Immunomedics/Gilead; Financial Interests, Institutional, Other, paid to institute: Ipsen; Financial Interests, Institutional, Advisory Board, honorarium for Ad Boards, paid to institute: Lilly; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board, paid to institute: Merck; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board & Lectures, paid to institute / Medical Writing: Novartis; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board & Lecture, paid to institute: Pierre Fabre; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board & Lecture, paid to institute: Prime/Medscape; Financial Interests, Institutional, Advisory Board, honorarium for Ad Board, paid to institute: Puma; Financial Interests, Institutional, Advisory Board, honorarium for Ad Boards & Lectures, paid to institute / Medical Writing: Roche; Financial Interests, Institutional, Invited Speaker, honorarium for Lecture, paid to institute: Samsung; Financial Interests, Institutional, Advisory Board, honorarium for Ad Boards, paid to institute: Seagen; Financial Interests, Institutional, Writing Engagements, paid to institute / Medical Writing: Vifor; Financial Interests, Personal, Licensing Fees, Method for predicting the response to cancer immunotherapy in cancer patients: EP18209672.7; Financial Interests, Personal, Licensing Fees, Method for predicting the response to CDK4/6 inhibitor therapy in cancer patients: EP21152186.9; Financial Interests, Personal, Licensing Fees, Method for predicting the response to an anti-HER2 containing therapy and/or chemotherapy in patients with breast cancer: EP15702464.7; Financial Interests, Institutional, Licensing Fees, paid to institute: VM Scope GmbH,. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.